Promazine hydrochloride Pharmacokinetics [Design Issues]

posted by pjs – India, 2015-05-13 13:51 (3269 d 11:23 ago) – Posting: # 14800
Views: 9,514

Dear all,

❝ Please suggest the innovator for Promazine hydrochloride in EMEA. We are developing two strengths 50mg and 25mg.


Wyeth pharma is the innovator for Promazine IN US (Approved in 1957 discontinued in 1997). IN EMEA couldnt find the active marketing status of innovator in any country. Yet generic tab were aprroved in 2015 (Is innovator tablet still available in the market or bibliographic application?).

❝ Also suggest about the pharmacokinetic linearity and intra subject variability of Promazine.


Have searched several times couldnt find a single BE study or linearity information. Promazine is reported to be highly variable after oral administration but no information regarding intrasubject CV.

One literature suggested dose proportional increase in urinary elimination after oral administration in the dose range. Promazine is highly permiable and soluble (BCS class 1). However no specific mention of pharmacokinetic linearity is there.

Regards,
PJS

Complete thread:

UA Flag
Activity
 Admin contact
22,993 posts in 4,828 threads, 1,655 registered users;
88 visitors (0 registered, 88 guests [including 2 identified bots]).
Forum time: 01:15 CEST (Europe/Vienna)

So far as I can remember,
there is not one word in the Gospels
in praise of intelligence.    Bertrand Russell

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5